Skip to main content

Posts

Showing posts with the label ramipril

Arteriosclerosis

April 2, 2007 AstraZeneca reported positive results from Phase III trial, (Measuring the effects on the thickness and endothelial media: 1 OfRosuvastatin evaluation), of Crestor for the treatment of atherosclerosis.  He joined the 24-month, randomized, double-blind, placebo-controlled trial 984 shows, and hypercholesterolaemic subjects with low risk of coronary artery disease andevidence of sub-clinical atherosclerosis.  The results showed thatsubjects with Crestor 40 mg experienced 0.0014 mm / year and a decrease in endothelial thickness meanmaximum media carotid artery, a sign of the burden of atherosclerosis, compared to the evolution of 0.0131 mm / year for those on placebo (P ≤ 0. 0001).  Inaddition, Crestor reduced demonstrated 48.8% in LDL-C and 8 1.  0% increasein HDL-C (both p ≤ placebo versus 0.0001).  AstraZeneca plans to submit NDA and Crestor MAAfor in the treatment of atherosclerosis in the first half of 2007. Scios issued positive results of the second phase of the tri